Test options before starting your treatment. In the lab. Without side effects.
Benefits of Reverse Clinical Engineering®
Requirements for the Reverse Clinical Engineering®
The Reverse Clinical Engineering® test procedure can be used to determine the optimal drug therapy for patients with malignant solid tumors. This requires fresh tissue from a biopsy or resection. The procedure cannot be applied to blood cancers (leukemias) or lymphatic cancers (lymphomas).
Your contact persons
Clinical Liaison Management
You are not sure if Reverse Clinical Engineering® is suitable for you? Or you would like to learn more about our method? Contact us or arrange a consultation.
How does Reverse Clinical Engineering® work?
Facts & Figures
In addition to treatment options, ASC Oncology provided me with optimal support during a time of uncertainty and gave me new perspectives on my life with the disease. My oncologist implemented the recommended medication – with success!
This new method by ASC Oncology’s effectively makes cancer patient care better than anything medicine has known before. The personalized approach significantly increases each patient’s quality of life and, at the same time, their chance of survival. From the outset, we as oncologists can avoid using ineffective drugs for our patients and
We go one step further. Sequencing tumors, for example, can reveal changes in the genetic material that may be used as a target for treatment of your tumor. However, it’s not clear if the targeted treatment will work in your case. Recent studies have shown that only a fraction of patients (0.8 – 3%) have been able to benefit from a therapy chosen for its sequencing results (Tannock & Hickman, 2019). In contrast, ASC Oncology’s Reverse Clinical Engineering® uses a person’s own tumor model to directly test the cancer drugs’ efficacy. This allows a prediction to be made about how you will respond to therapy. Find out more about the test procedure under Science.
Your treating physician removes a small piece of cancer tissue during your surgery or biopsy and sends this directly to ASC Oncology’s laboratory. Our team of scientists multiplies the living tumor cells in the lab and grows “avatars” of your tumor, called ‘tumor organoids’. These avatars of the tumor can be used to test drugs that may be candidates for treating your tumor, allowing the most effective anticancer drug to be determined before therapy begins. Our results are an important decision-making aid for personalized anticancer therapy. Compared to following standard guideline recommended therapy, this approach has higher chances of treatment success. View a complete list of steps of the procedure here.
No, ASC Oncology does not replace your oncologist, but provides you and your doctor with additional information. Every patient and every cancer is unique. The results of the Reverse Clinical Engineering® test procedure will tell you and your oncologist which drugs are likely to be effective on your individual tumor. These additional insights increase the chance of receiving effective drug therapy right from the start and avoiding ineffective therapies along with potential side effects.
It varies. Depending on the quality of the tumor sample and the cancer entity, growing PD3D® tumor models can take different amounts of time. On average, the Reverse Clinical Engineering® test procedure takes 28 days from receiving the sample to preparing the final report.
Please do not send a sample without letting us know in advance. Please contact us at 0800 6988667 or use our online form to register a patient and send a sample. We will organize the pick-up and provide everything needed to transport it as quickly as possible – even for short-term requests. Take a look at our overview of the procedure.
ASC Oncology was founded in 2019 by leading scientists in the fields of pathology, biology, biochemistry, biotechnology, and tumor biology. We are an interdisciplinary team of experts, who together with lawyers and business information specialists, are dedicated in our fight against cancer and to advance precision oncology.
ASC Oncology benefits from years of expertise in 3D cell culture and the latest findings in the field of tumor organoid research through close collaboration with its sister company CELLphenomics, which was founded in 2014. In addition, we are supported by a top-class advisory board consisting of physicians, scientists, and patient representatives.